Sean Ong
@seanong.bsky.social
ID doc and joint PhD candidate at University of Toronto + University of Melbourne. Talk to me about clinical trial design and methodology, bloodstream infections, S. aureus, and Gram negatives 🦠
🇸🇬🇨🇦🇦🇺
🇸🇬🇨🇦🇦🇺
Reposted by Sean Ong
Hi Gabriele! Guess what- with @germhuntermd.bsky.social & quite a few others, we are gearing up to launch an #IDjournalclub on Bsky and it looks like this paper is the one we'll start with. 😊 We will get that going soooon!! (Also, Communicable will work on a follow-up POET2 ep!)
#IDSky #MedSky
#IDSky #MedSky
September 9, 2026 at 8:16 AM
Hi Gabriele! Guess what- with @germhuntermd.bsky.social & quite a few others, we are gearing up to launch an #IDjournalclub on Bsky and it looks like this paper is the one we'll start with. 😊 We will get that going soooon!! (Also, Communicable will work on a follow-up POET2 ep!)
#IDSky #MedSky
#IDSky #MedSky
Reposted by Sean Ong
Demystify clinical trial design & enhance your research toolkit!📊✨
Join our statistical seminars supported by @advance-id.bsky.social & @who.int
Explore clinical trial theory & real-life examples with global experts. Master the numbers in the mission against disease here: ad-id.co/stats
Join our statistical seminars supported by @advance-id.bsky.social & @who.int
Explore clinical trial theory & real-life examples with global experts. Master the numbers in the mission against disease here: ad-id.co/stats
August 14, 2026 at 9:00 AM
Demystify clinical trial design & enhance your research toolkit!📊✨
Join our statistical seminars supported by @advance-id.bsky.social & @who.int
Explore clinical trial theory & real-life examples with global experts. Master the numbers in the mission against disease here: ad-id.co/stats
Join our statistical seminars supported by @advance-id.bsky.social & @who.int
Explore clinical trial theory & real-life examples with global experts. Master the numbers in the mission against disease here: ad-id.co/stats
Reposted by Sean Ong
📣We rely more & more on #AI for literature review
So how did 6 large language models compare to humans when extracting data from #RCTs for a systematic review?
Not very well: overall #LLM concordance was 0.58-0.75.
#IDSky
@steventong.bsky.social
@seanong.bsky.social
cmi-comms.org/article/S295...
So how did 6 large language models compare to humans when extracting data from #RCTs for a systematic review?
Not very well: overall #LLM concordance was 0.58-0.75.
#IDSky
@steventong.bsky.social
@seanong.bsky.social
cmi-comms.org/article/S295...
A proof-of-concept performance evaluation of six large language models for semiautomated data extraction in a systematic review on infectious diseases clinical trials
Large language models (LLMs) are increasingly being used in the systematic review
process. Our objective was to explore data extraction performance of six LLMs from
a published systematic review of in...
cmi-comms.org
August 11, 2026 at 7:49 AM
📣We rely more & more on #AI for literature review
So how did 6 large language models compare to humans when extracting data from #RCTs for a systematic review?
Not very well: overall #LLM concordance was 0.58-0.75.
#IDSky
@steventong.bsky.social
@seanong.bsky.social
cmi-comms.org/article/S295...
So how did 6 large language models compare to humans when extracting data from #RCTs for a systematic review?
Not very well: overall #LLM concordance was 0.58-0.75.
#IDSky
@steventong.bsky.social
@seanong.bsky.social
cmi-comms.org/article/S295...
Reposted by Sean Ong
Rationalizing Heterogeneity in Staphylococcus aureus Bacteremia: Current Progress and Future Goals
✅ Just Accepted
🔗 https://bit.ly/4vTJLHo
✅ Just Accepted
🔗 https://bit.ly/4vTJLHo
July 10, 2026 at 3:22 AM
Rationalizing Heterogeneity in Staphylococcus aureus Bacteremia: Current Progress and Future Goals
✅ Just Accepted
🔗 https://bit.ly/4vTJLHo
✅ Just Accepted
🔗 https://bit.ly/4vTJLHo
Reposted by Sean Ong
Bringing #AMR into the outcome assessment of duration trials with the new DOOR-FRAME is very welcome!
Larger samples and systematic AMR assessment among participants will be likely required to prove benefit
academic.oup.com/ofid/article... #IDSky #AMSsky
Awesome work by @seanong.bsky.social et al
Larger samples and systematic AMR assessment among participants will be likely required to prove benefit
academic.oup.com/ofid/article... #IDSky #AMSsky
Awesome work by @seanong.bsky.social et al
June 23, 2026 at 1:36 AM
Bringing #AMR into the outcome assessment of duration trials with the new DOOR-FRAME is very welcome!
Larger samples and systematic AMR assessment among participants will be likely required to prove benefit
academic.oup.com/ofid/article... #IDSky #AMSsky
Awesome work by @seanong.bsky.social et al
Larger samples and systematic AMR assessment among participants will be likely required to prove benefit
academic.oup.com/ofid/article... #IDSky #AMSsky
Awesome work by @seanong.bsky.social et al
Reposted by Sean Ong
Excited to share an article that I've long awaited to share seeking to answer: What is the right dose of cephalexin/cefadroxil for SSTIs?
We reviewed clinical studies & conducted PTA sims to elucidate this #IDSky @absteward.bsky.social
accpjournals.onlinelibrary.wiley.com/doi/10.1002/...
We reviewed clinical studies & conducted PTA sims to elucidate this #IDSky @absteward.bsky.social
accpjournals.onlinelibrary.wiley.com/doi/10.1002/...
Getting It Right the Second Time: How Can we Optimize First‐Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?
Optimal cephalexin and cefadroxil dosing for skin and soft tissue infections (SSTIs) is unclear. We summarize clinical and pharmacokinetic/pharmacodynamic (PK/PD) data that compare dosing strategies ...
accpjournals.onlinelibrary.wiley.com
June 11, 2026 at 12:48 PM
Excited to share an article that I've long awaited to share seeking to answer: What is the right dose of cephalexin/cefadroxil for SSTIs?
We reviewed clinical studies & conducted PTA sims to elucidate this #IDSky @absteward.bsky.social
accpjournals.onlinelibrary.wiley.com/doi/10.1002/...
We reviewed clinical studies & conducted PTA sims to elucidate this #IDSky @absteward.bsky.social
accpjournals.onlinelibrary.wiley.com/doi/10.1002/...
Reposted by Sean Ong
ESCMID 2026 highlights
COBRA Trial – One day is enough
Dutch RCT: 1 day of antibiotics after ERCP drainage for cholangitis was non‑inferior to 4–7 days.
Bottom line: Antibiotic durations can safely be much shorter once source control is achieved.
#IDSky
clarityinitiative.org/escmid-2026-...
COBRA Trial – One day is enough
Dutch RCT: 1 day of antibiotics after ERCP drainage for cholangitis was non‑inferior to 4–7 days.
Bottom line: Antibiotic durations can safely be much shorter once source control is achieved.
#IDSky
clarityinitiative.org/escmid-2026-...
Clarity Initiative
Clinical Literature Appraisal and Research education in InfecTious diseases
clarityinitiative.org
May 14, 2026 at 11:37 AM
ESCMID 2026 highlights
COBRA Trial – One day is enough
Dutch RCT: 1 day of antibiotics after ERCP drainage for cholangitis was non‑inferior to 4–7 days.
Bottom line: Antibiotic durations can safely be much shorter once source control is achieved.
#IDSky
clarityinitiative.org/escmid-2026-...
COBRA Trial – One day is enough
Dutch RCT: 1 day of antibiotics after ERCP drainage for cholangitis was non‑inferior to 4–7 days.
Bottom line: Antibiotic durations can safely be much shorter once source control is achieved.
#IDSky
clarityinitiative.org/escmid-2026-...
Reposted by Sean Ong
📣 New publication: Andes hantavirus outbreak on a cruise ship - an ESCMID Emerging Infections Subcommittee (EIS) rapid assessment
www.clinicalmicrobiologyandinfection.org/article/S119...
www.clinicalmicrobiologyandinfection.org/article/S119...
Andes hantavirus outbreak on a cruise ship - an ESCMID Emerging Infections Subcommittee (EIS) rapid assessment
The ongoing cluster of hantavirus infections associated with the cruise ship MV Hondius
represents an unusual but instructive event at the intersection of zoonotic spillover,
human mobility, confined ...
www.clinicalmicrobiologyandinfection.org
May 13, 2026 at 3:36 AM
📣 New publication: Andes hantavirus outbreak on a cruise ship - an ESCMID Emerging Infections Subcommittee (EIS) rapid assessment
www.clinicalmicrobiologyandinfection.org/article/S119...
www.clinicalmicrobiologyandinfection.org/article/S119...
Reposted by Sean Ong
Highlights from ESCMID Global 2026?
@gurujosh.bsky.social asked CLARITY faculty: @angelahuttner.bsky.social @erinmccreary.bsky.social @marcbonten.bsky.social @seanong.bsky.social @ashabowen.bsky.social and others (not on BlueSky).
#IDSky
clarityinitiative.org/escmid-2026-...
Any that we missed?
@gurujosh.bsky.social asked CLARITY faculty: @angelahuttner.bsky.social @erinmccreary.bsky.social @marcbonten.bsky.social @seanong.bsky.social @ashabowen.bsky.social and others (not on BlueSky).
#IDSky
clarityinitiative.org/escmid-2026-...
Any that we missed?
Clarity Initiative
Clinical Literature Appraisal and Research education in InfecTious diseases
clarityinitiative.org
May 14, 2026 at 1:04 AM
Highlights from ESCMID Global 2026?
@gurujosh.bsky.social asked CLARITY faculty: @angelahuttner.bsky.social @erinmccreary.bsky.social @marcbonten.bsky.social @seanong.bsky.social @ashabowen.bsky.social and others (not on BlueSky).
#IDSky
clarityinitiative.org/escmid-2026-...
Any that we missed?
@gurujosh.bsky.social asked CLARITY faculty: @angelahuttner.bsky.social @erinmccreary.bsky.social @marcbonten.bsky.social @seanong.bsky.social @ashabowen.bsky.social and others (not on BlueSky).
#IDSky
clarityinitiative.org/escmid-2026-...
Any that we missed?
Reposted by Sean Ong
We looked at empiric B-lactam antibiotics in MRSA bacteraemia and BC persistence and AKI, using CAMERA2 dataset.
Groups: none, early (only empiric B-lactam), late (only after trial enrolment), throughout (empiric and after enrolment).
#IDSky
www.clinicalmicrobiologyandinfection.org/article/S119...
Groups: none, early (only empiric B-lactam), late (only after trial enrolment), throughout (empiric and after enrolment).
#IDSky
www.clinicalmicrobiologyandinfection.org/article/S119...
May 6, 2026 at 1:43 AM
We looked at empiric B-lactam antibiotics in MRSA bacteraemia and BC persistence and AKI, using CAMERA2 dataset.
Groups: none, early (only empiric B-lactam), late (only after trial enrolment), throughout (empiric and after enrolment).
#IDSky
www.clinicalmicrobiologyandinfection.org/article/S119...
Groups: none, early (only empiric B-lactam), late (only after trial enrolment), throughout (empiric and after enrolment).
#IDSky
www.clinicalmicrobiologyandinfection.org/article/S119...
Reposted by Sean Ong
🔥 💥Late-Breakers |COBRA RCT
1-day of antibiotic treatment after adequate endoscopic biliary drainage is non-inferior to 4-7 days in adults with acute cholangitis.
💡 Shorter is better+source control
Practice-changing? #ESCMIDGlobal2026 #idsky
1-day of antibiotic treatment after adequate endoscopic biliary drainage is non-inferior to 4-7 days in adults with acute cholangitis.
💡 Shorter is better+source control
Practice-changing? #ESCMIDGlobal2026 #idsky
April 20, 2026 at 4:40 PM
🔥 💥Late-Breakers |COBRA RCT
1-day of antibiotic treatment after adequate endoscopic biliary drainage is non-inferior to 4-7 days in adults with acute cholangitis.
💡 Shorter is better+source control
Practice-changing? #ESCMIDGlobal2026 #idsky
1-day of antibiotic treatment after adequate endoscopic biliary drainage is non-inferior to 4-7 days in adults with acute cholangitis.
💡 Shorter is better+source control
Practice-changing? #ESCMIDGlobal2026 #idsky
Reposted by Sean Ong
Nice presentation from @seanong.bsky.social about DOOR/Radar at #ESCMIDGlobal2026
My main worry is lower ranked components dominating
Sarah Walker discussed this issue in her excellent Bradford Hill lecture (recording in link)
My main worry is lower ranked components dominating
Sarah Walker discussed this issue in her excellent Bradford Hill lecture (recording in link)
April 17, 2026 at 2:17 PM
Nice presentation from @seanong.bsky.social about DOOR/Radar at #ESCMIDGlobal2026
My main worry is lower ranked components dominating
Sarah Walker discussed this issue in her excellent Bradford Hill lecture (recording in link)
My main worry is lower ranked components dominating
Sarah Walker discussed this issue in her excellent Bradford Hill lecture (recording in link)
Reposted by Sean Ong
The 3rd and 4th commentaries on recent ID trials are up on the CLARITY website (we aim to publish in depth reviews of important ID stuies).
This time looking at the GAMECHANGER trial:
clarityinitiative.org/commentaries...
@erinmccreary.bsky.social with Ahmad Mourad
@gurujosh.bsky.social
#IDSky
This time looking at the GAMECHANGER trial:
clarityinitiative.org/commentaries...
@erinmccreary.bsky.social with Ahmad Mourad
@gurujosh.bsky.social
#IDSky
How Do We Win? The GAME CHANGER Trial
Erin K. McCreary, PharmD (1), Ahmad Mourad, MD MHS (2, 3)
clarityinitiative.org
January 1, 2026 at 11:50 PM
The 3rd and 4th commentaries on recent ID trials are up on the CLARITY website (we aim to publish in depth reviews of important ID stuies).
This time looking at the GAMECHANGER trial:
clarityinitiative.org/commentaries...
@erinmccreary.bsky.social with Ahmad Mourad
@gurujosh.bsky.social
#IDSky
This time looking at the GAMECHANGER trial:
clarityinitiative.org/commentaries...
@erinmccreary.bsky.social with Ahmad Mourad
@gurujosh.bsky.social
#IDSky
Reposted by Sean Ong
New article about how to manage Staphylococcus aureus bacteremia. Led by Hadar Mudrik-Zohar. Includes @seanong.bsky.social @drtoddlee.bsky.social
#IDSky #SNAP_trial
www.sciencedirect.com/science/arti...
#IDSky #SNAP_trial
www.sciencedirect.com/science/arti...
Navigating the Challenges in Staphylococcus aureus Bloodstream Infection: A Practical Guide to Management
www.sciencedirect.com
December 4, 2025 at 2:53 AM
New article about how to manage Staphylococcus aureus bacteremia. Led by Hadar Mudrik-Zohar. Includes @seanong.bsky.social @drtoddlee.bsky.social
#IDSky #SNAP_trial
www.sciencedirect.com/science/arti...
#IDSky #SNAP_trial
www.sciencedirect.com/science/arti...
A group of ID clinical researchers passionate about clinical research and evidence appraisal has just launched the CLARITY initiative (clarityinitiative.org), which aims to improve the generation and interpretation of evidence in ID and Microbiology.
Clarity Initiative
Clinical Literature Appraisal and Research education in InfecTious diseases
clarityinitiative.org
November 30, 2025 at 11:40 PM
A group of ID clinical researchers passionate about clinical research and evidence appraisal has just launched the CLARITY initiative (clarityinitiative.org), which aims to improve the generation and interpretation of evidence in ID and Microbiology.
Our new paper in @cmijournal.bsky.social:
www.clinicalmicrobiologyandinfection.org/article/S119...
We use the BALANCE and CAMERA2 trials as case studies to illustrate the use of the different methods available for analysis of hierarchical composite endpoints.
#IDSky @steventong.bsky.social
www.clinicalmicrobiologyandinfection.org/article/S119...
We use the BALANCE and CAMERA2 trials as case studies to illustrate the use of the different methods available for analysis of hierarchical composite endpoints.
#IDSky @steventong.bsky.social
Comparing different methods for analyzing hierarchical composite endpoints: two illustrative case studies with post-hoc analyses of the BALANCE and CAMERA2 randomized clinical trials.
Hierarchical composite endpoints (HCEs) are increasingly being used in infectious
disease research. In this paper, we illustrate different methods for analyzing HCEs
in post-hoc analyses of the BALANC...
www.clinicalmicrobiologyandinfection.org
November 30, 2025 at 11:30 PM
Our new paper in @cmijournal.bsky.social:
www.clinicalmicrobiologyandinfection.org/article/S119...
We use the BALANCE and CAMERA2 trials as case studies to illustrate the use of the different methods available for analysis of hierarchical composite endpoints.
#IDSky @steventong.bsky.social
www.clinicalmicrobiologyandinfection.org/article/S119...
We use the BALANCE and CAMERA2 trials as case studies to illustrate the use of the different methods available for analysis of hierarchical composite endpoints.
#IDSky @steventong.bsky.social
Reposted by Sean Ong
The draft for the 2026 IDSA/ESCMID clinical practice guidelines on 𝘚. 𝘢𝘶𝘳𝘦𝘶𝘴 bacteraemia is now available for public consultation. Get your copy of the manuscript and submit your feedback before 15 December 2025.
https://ow.ly/HZao50XwVYg
#IDSky #clinmicro
https://ow.ly/HZao50XwVYg
#IDSky #clinmicro
November 27, 2025 at 6:35 AM
The draft for the 2026 IDSA/ESCMID clinical practice guidelines on 𝘚. 𝘢𝘶𝘳𝘦𝘶𝘴 bacteraemia is now available for public consultation. Get your copy of the manuscript and submit your feedback before 15 December 2025.
https://ow.ly/HZao50XwVYg
#IDSky #clinmicro
https://ow.ly/HZao50XwVYg
#IDSky #clinmicro
Reposted by Sean Ong
@seanong.bsky.social is giving his PhD oration today at 12.30pm AEDT. If you are free, you will learn heaps about clinical trials in infectious diseases. It's been an incredible PhD journey!
unimelb.zoom.us/j/8944229688...
@thedohertyinst.bsky.social
unimelb.zoom.us/j/8944229688...
@thedohertyinst.bsky.social
November 16, 2025 at 10:53 PM
@seanong.bsky.social is giving his PhD oration today at 12.30pm AEDT. If you are free, you will learn heaps about clinical trials in infectious diseases. It's been an incredible PhD journey!
unimelb.zoom.us/j/8944229688...
@thedohertyinst.bsky.social
unimelb.zoom.us/j/8944229688...
@thedohertyinst.bsky.social
Reposted by Sean Ong
New Research
Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial
www.thelancet.com/journals/lan...
Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial
www.thelancet.com/journals/lan...
Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial
Non-adherence in BALANCE was significantly associated with a range of important prognostic
factors, which might have introduced bias. Causal inference methods addressing this
bias showed a consistent ...
www.thelancet.com
November 12, 2025 at 8:58 AM
New Research
Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial
www.thelancet.com/journals/lan...
Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial
www.thelancet.com/journals/lan...
Hot off the press at @thelancetinfdis.bsky.social: our paper diving into non-adherence in the BALANCE trial. We identify factors associated with protocol non-adherence, and evaluate the impact of potential bias on trial results.
authors.elsevier.com/a/1m5He5E-Uo...
@steventong.bsky.social #IDSky
authors.elsevier.com/a/1m5He5E-Uo...
@steventong.bsky.social #IDSky
authors.elsevier.com
November 12, 2025 at 12:55 AM
Hot off the press at @thelancetinfdis.bsky.social: our paper diving into non-adherence in the BALANCE trial. We identify factors associated with protocol non-adherence, and evaluate the impact of potential bias on trial results.
authors.elsevier.com/a/1m5He5E-Uo...
@steventong.bsky.social #IDSky
authors.elsevier.com/a/1m5He5E-Uo...
@steventong.bsky.social #IDSky
We are looking for candidates for a new fully-funded joint PhD position at the Universities of Toronto and Melbourne, working on RCTs in bloodstream infection (BALANCE+, SNAP, STRAP).
More info here: forms.gle/H9TXEMkwM1cb...
Please spread far and wide!
@steventong.bsky.social #IDSky
More info here: forms.gle/H9TXEMkwM1cb...
Please spread far and wide!
@steventong.bsky.social #IDSky
forms.gle
October 27, 2025 at 5:44 AM
We are looking for candidates for a new fully-funded joint PhD position at the Universities of Toronto and Melbourne, working on RCTs in bloodstream infection (BALANCE+, SNAP, STRAP).
More info here: forms.gle/H9TXEMkwM1cb...
Please spread far and wide!
@steventong.bsky.social #IDSky
More info here: forms.gle/H9TXEMkwM1cb...
Please spread far and wide!
@steventong.bsky.social #IDSky
I owe a lot to the site formerly known as Twitter (it's where I found my amazing joint PhD position thanks to a fortuitous post by @steventong.bsky.social), but it's completely unusable now and full of irrelevant material that I don't want to see. I no longer use it, and am firmly Team BlueSky!
New pro/con perspective piece by @drneilstone.bsky.social & yours truly
Joining the X-odus: Contrasting perspectives on whether infection specialists should leave X (formerly Twitter)
That I'm sharing it here belies where I stand on the issue
www.cmi-comms.org/article/S295... #IDSky
Joining the X-odus: Contrasting perspectives on whether infection specialists should leave X (formerly Twitter)
That I'm sharing it here belies where I stand on the issue
www.cmi-comms.org/article/S295... #IDSky
Joining the X-odus: Contrasting perspectives on whether infection specialists should leave X (formerly Twitter)
Social media is a cultural and communications phenomenon that is an integral part
of life in the 2020s. Twitter was founded in 2006 and became a leading social media
platform with an active user base ...
www.cmi-comms.org
October 16, 2025 at 11:44 AM
I owe a lot to the site formerly known as Twitter (it's where I found my amazing joint PhD position thanks to a fortuitous post by @steventong.bsky.social), but it's completely unusable now and full of irrelevant material that I don't want to see. I no longer use it, and am firmly Team BlueSky!
Reposted by Sean Ong
David Paterson and the ADVANCE-ID team are doing a lot of work for us summarizing recent literature on bacterial & fungal infections & therapies. If you aren't already receiving their bimonthly newsletters, you should! ad-id.co/subscribe
#IDSky #Clinmicro
#IDSky #Clinmicro
October 15, 2025 at 4:42 AM
David Paterson and the ADVANCE-ID team are doing a lot of work for us summarizing recent literature on bacterial & fungal infections & therapies. If you aren't already receiving their bimonthly newsletters, you should! ad-id.co/subscribe
#IDSky #Clinmicro
#IDSky #Clinmicro
Our new paper in @cmijournal.bsky.social led by the brilliant Hadrien Moffroid, a junior colleague in Melbourne. We examined international funding flows in ID RCTs published in selected high-impact journals over a 10-year period.
doi.org/10.1016/j.cm...
@steventong.bsky.social #IDSky
doi.org/10.1016/j.cm...
@steventong.bsky.social #IDSky
September 29, 2025 at 8:57 AM
Our new paper in @cmijournal.bsky.social led by the brilliant Hadrien Moffroid, a junior colleague in Melbourne. We examined international funding flows in ID RCTs published in selected high-impact journals over a 10-year period.
doi.org/10.1016/j.cm...
@steventong.bsky.social #IDSky
doi.org/10.1016/j.cm...
@steventong.bsky.social #IDSky
Reposted by Sean Ong
New post-hoc Camera-2 📷 post-hoc analysis out today regarding adherence to quality metrics in MRSA bacteremia.
Compared to similar non-trial population w/ MRSA bacteremia:
-No difference in 🪦, BUT
-non-trial had less following of quality metrics (see ⬇️)
#IDSky
jamanetwork.com/journals/jam...
Compared to similar non-trial population w/ MRSA bacteremia:
-No difference in 🪦, BUT
-non-trial had less following of quality metrics (see ⬇️)
#IDSky
jamanetwork.com/journals/jam...
Quality-of-Care Indicator Adherence and Mortality Outcomes in MRSA Bacteremia
This post hoc analysis of a randomized clinical trial investigates whether patient participation in clinical trials is associated with practitioner adherence to methicillin-resistant Staphylococcus au...
jamanetwork.com
July 27, 2025 at 12:59 AM
New post-hoc Camera-2 📷 post-hoc analysis out today regarding adherence to quality metrics in MRSA bacteremia.
Compared to similar non-trial population w/ MRSA bacteremia:
-No difference in 🪦, BUT
-non-trial had less following of quality metrics (see ⬇️)
#IDSky
jamanetwork.com/journals/jam...
Compared to similar non-trial population w/ MRSA bacteremia:
-No difference in 🪦, BUT
-non-trial had less following of quality metrics (see ⬇️)
#IDSky
jamanetwork.com/journals/jam...